TNX-650
From Wikipedia, the free encyclopedia
TNX-650 is a medication for refractory Hodgkin's lymphoma under development by Tanox. It is currently in a phase 1 clinical trial
It is a monoclonal antibody intended to target the production of interleukin 13.[1]
[edit] References
- ^ First Patient Dosed In Phase 1 Trial Of Tanox, Inc.'s TNX-650 - News, Search Jobs, Events. Retrieved on 2007-07-08.
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
